• Dr James Hodge lab in collaboration with Pharmasum Therapeutics, Norway provide preclinical validation of a potential new Alzheimer’s disease and Down syndrome drug published in Frontiers in Pharmacology:

“DYRK1A inhibitor mediated rescue of Drosophila models of Alzheimer's disease-Down Syndrome phenotypes” Bangfu Zhu, Tom Parsons, Wenche Stensen, John S Mjøen Svendsen, Anders Fugelli & James J L Hodge, Frontiers in Pharmacology http://journal.frontiersin.org/article/10.3389/fphar.2022.881385/

• Dr James Hodge lab working with Illuminos Therapeutics and Arizona University provide further validation of DYRK1A as a drug target for Down’s syndrome and Alzheimer’s disease published in Scientific Reports:

“DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity" by Bangfu Zhu, Tom Parsons, Christopher Foley, Yeng Shaw, Travis Dunckley, Christopher Hulme & James J. L. Hodge Scientific Reports, https://rdcu.be/cWanY

• Dr James Hodge’s Lab working with Dr Anir Majumdar’s team at the Children’s Hospital, Bristol has published work characterising a new rare genetic disease and neuropathy in Clinical Genetics:

“Hereditary spastic paraparesis presenting as cerebral palsy due to ADD3 variant with mechanistic insight provided by a Drosophila γ-adducin model” Sanchez Marco SB, Buhl E, Firth R, Zhu B, Gainsborough M, Beleza-Meireles A, Moore S, Caswell R, Stals K, Ellard S, Kennedy C, Hodge JJL, Majumdar A. http://doi.org/10.1111/cge.14220